Despite the widespread use of a live attenuated vaccine, measles remains the leading killer among vaccine preventable diseases of childhood, responsible for approximately 1 million deaths annually, particularly among infants less than 9 months of age (31) . This mortality is in part due to the rapid decline of maternal antibodies among infants in developing countries (11) and the policy of the World Health Organization to recommend only immunization with standard dose measles virus (MV) vaccine from 9 months of age.
Among the morbillivirus group of paramyxoviruses, the fusion (F) and hemagglutinin (HA) surface glycoproteins play a vital role in the induction of protective immunity. Fusion protein is synthesized as an inactive precursor, F 0 , that is subsequently cleaved by host cell proteases to yield two active disulfide-linked subunits, F 1 and F 2 . The F protein is responsible for virus penetration through fusion of viral and host cell membranes, cell fusion, and hemolysis (4) . Cell fusion mediated by F protein is responsible for the characteristic cytopathic effect seen in paramyxovirus infections. Vaccinia virus recombinants expressing either the H or F gene of rinderpest virus have been shown to induce virus-neutralizing antibodies and to completely protect against cattle plague (32) . For MV, induction of antibody responses to F protein is essential for protection, as evidenced by the development of severe atypical disease in children years following immunization with inactivated MV vaccine, who developed adequate neutralizing and hemagglutination inhibiting antibodies but no antibodies to the F protein (15) . Vaccinia virus recombinants encoding F protein have been shown to induce MV-neutralizing antibodies in mice and to protect them from fatal acute measles encephalitis (7) . Furthermore, mouse monoclonal antibodies raised to recombinant F protein neutralize virus infectivity in vitro and protect against measles encephalitis in mice (13) . Therefore, any new MV vaccines must also induce neutralizing and hemolysis-inhibiting antibodies to the F protein.
As infants have a higher case fatality rate and suffer more from the delayed impact of MV infection (1), peptide-based vaccines against measles represent a stable alternative to live, attenuated vaccines which may be administered early in life, even in the presence of maternal immunity. Synthetic peptides representing specific linear epitopes of viral proteins have been shown to be immunogenic and to induce both antipeptide and neutralizing antiviral antibodies in vivo (8, 18) . Identification of protective B-and T-cell epitopes on specific viral proteins is thus vital for the development of rationally designed synthetic peptide vaccines. Previous studies on the F protein of MV have identified an immunodominant helper T-cell epitope in mice and humans (19) , while screening of a solid-phase peptide library with a mouse monoclonal anti-F antibody has allowed the identification of peptide mimics of conformational B-cell epitopes (23) , one of which actively protected mice from fatal encephalitis. Mapping of linear F peptides by using serum from healthy human donors has previously identified 7 to 10 antigenic regions which were located along the whole F-protein sequence; however, the function of these antigenic regions remains unclear (28) .
This study describes the identification of a major antigenic epitope, recognized by acute postinfection sera, using overlapping synthetic F peptides. The immunogenicity of a synthetic peptide representing this epitope was assessed in mice, and the antipeptide antibodies generated cross-reacted with MV and could be shown to inhibit MV infectivity in vitro. Finally, these antipeptide antibodies were shown to passively protect mice against fatal encephalitis following challenge with a neuroadapted strain of MV.
MATERIALS AND METHODS
Peptide synthesis. Overlapping pentadecapeptides representing amino acids (aa) 33 to 550 (excluding the transmembrane regions) of the Edmonston strain of MV F glycoprotein (22) were synthesized manually by rapid multiple peptide synthesis (Du Pont) (17) . Briefly, 44 overlapping peptides were synthesized by using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry with 4-(2Ј,4Ј-dimethyloxphenyl-Fmoc amino-methyl)-phenoxy resin. Each peptide was 15 aa long and had a five-residue overlap with the following peptide. Peptides were analyzed by high-performance liquid chromatography (Shimatzu, Tokyo, Japan). The molecular weights of peptides were analyzed by fast atom bombardment mass spectrometry at the London School of Pharmacy. Four additional 8-mer peptides and two 15-mer substitution peptides were later synthesized to delineate regions of interest on a peptide of the F protein, using an automated peptide synthesizer (PepSynthesizer; PerSeptive Biosystems, Watford, Hertfordshire, England).
Acute MV sera. Acute MV sera were obtained from 4-to 36-month-old children in Guinea-Bissau who had measles during a severe measles epidemic in 1991. A clinical diagnosis of measles was reached, and sera were collected up to 4 weeks following the appearance of a maculopapular rash. Control sera were provided by infants enrolled in a high-dose Edmonston-Zagreb MV vaccine trial. Sera were obtained from infants at 5 or 9 months of age, immediately prior to vaccination. All sera were heat inactivated at 56°C for 0.5 h before use. Prevaccination anti-MV antibodies were measured by hemagglutination inhibition (27) .
Mice. ELISA. (i) Detection of anti-MV IgG antibodies. Immunoglobulin G (IgG) anti-MV antibody activity in human postmeasles sera and the ability of mouse antipeptide sera to cross-react with MV was assessed by enzyme-linked immunosorbent assay (ELISA), using sucrose density gradient-purified MV and control (uninfected Vero cell) antigens (5) . Serial twofold dilutions of sera in blocking buffer were then added, and the plates were incubated for 45 min at 37°C. To each well was added 50 l of a 1/5,000 dilution of peroxidase-conjugated goat anti-human IgG (heavy plus light chain; Jackson Immunochemicals) or 1/2,000 dilution of peroxidase-conjugated rabbit anti-mouse IgG (heavy plus light chain; Nordic), and the plates were incubated for a further 45 min at 37°C. Plates were washed, and bound enzyme was detected by the addition of enzyme substrate (0.04% o-phenylenediamine-0.004% hydrogen peroxide in phosphate-citrate buffer [pH 5.5]) at 50 l/well. The reaction was stopped after 10 min with the addition of 2 M H 2 SO 4 (50 l/well), and the A 490 values were read on a Titertek Multiskan (Dynatech MR5000). Second International Reference anti-MV human serum (66/202; National Institute of Biological Standards and Controls, Potters Bar, Hertfordshire, England) and pooled serum from MV-immunized BALB/c mice were included as positive human and mouse controls, respectively. A corrected optical density (OD) value at A 490 was obtained for each sample by subtraction of the OD in control antigen wells from the OD in the protein antigen wells.
(ii) Reactivity of human sera with F peptides. The antigenic profile of F protein was assessed by using 44 overlapping 15-mer peptides as solid-phase antigens on ELISA. Human sera were added at a dilution of 1/200 to all wells of the plate and incubated for 45 min at 37°C; the remainder of the assay was performed as described above. The reactivity of serum with each peptide, expressed as ⌬OD at A 490 , was determined by subtraction of the OD of serum in empty blocked wells from the OD of serum reacting with the specified peptide antigen well.
(iii) Detection of mouse IgG antipeptide antibodies. Mouse IgG antipeptide antibodies induced following peptide immunization were determined by enzyme immunoassay. Microtiter plates (Nunc, Roskilde, Denmark) were coated overnight at 4°C with the appropriate peptide in 0.1 M carbonate-bicarbonate buffer. Plates were washed, and remaining binding sites were blocked as described above. Twofold serial dilutions of mouse antipeptide serum were added at 50 l/well and incubated for an hour at 37°C. After washing, the remaining steps of the assay were carried out as before. Antipeptide antibody titers were calculated as log 10 of the reciprocal of the antibody dilution giving an OD greater than 0.2 at A 490 . Irrelevant peptides from the F protein were routinely included in the assays to ensure the specificity of the binding detected.
(iv) Affinity assays. The relative affinities of human anti-MV antibodies to the relevant peptide and mouse antipeptide IgG antibodies to the homologous peptide were determined by a solid-phase enzyme inhibition assay (21) . Appropriate dilutions of serum in blocking buffer were preincubated with 0.5 log 10 dilutions of inhibiting peptide at 37°C for 1 h. The relative antipeptide antibody affinity was determined as the reciprocal of the molar concentration which gave 50% inhibition of the binding observed in the absence of inhibiting peptide.
Virus neutralization. Plaque neutralization assays were performed as described previously (2) . Vero cells were seeded overnight at 2 ϫ 10 4 cells/well in 96-well flat-bottom culture plates (Nunc); 30 PFU of the Edmonston strain of MV was added to twofold dilutions of heat-inactivated mouse serum and incubated for 1 h at 37°C in 5% CO 2 . The virus-serum mixtures were added to wells containing Vero cells and incubated for a further hour at 37°C in 5% CO 2 , the medium was discarded, and a carboxymethylcellulose overlay was added. Plates were observed daily for plaque formation, and up to 4 days later, cell sheets were fixed with 20% formaldehyde in phosphate-buffered saline and stained with 0.1% crystal violet. Endpoint titration was determined as the dilution of serum which reduced the plaque number by 50% of the mean value observed in virus control wells. Normal mouse serum and pooled serum from MV-immunized BALB/c mice were included as negative and positive controls, respectively.
Cell-cell fusion inhibition. MV was added to a monolayer of Vero cells at 0.1 PFU/cell. After 1 h, the cells were washed and prediluted test and control sera were added. Appropriate positive and negative controls were included. Plates were read 24 to 48 h later (29) .
Statistical analyses. Comparisons between antipeptide antibody affinities raised in the two groups of mice and among the polyclonal human sera were assessed by the Mann-Whitney U test (nonparametric method rank test). Comparisons between two groups of mice in protection studies were assessed by Fisher's exact two-tailed test, comparing the frequency of survival and mortality in immunized mice versus control groups.
RESULTS
Epitope mapping of F protein by using synthetic peptides and human serum. (Fig. 1a) . Furthermore, none of 15 serum samples obtained prevaccination from infants with anti-MV antibodies Ͻ1/20 (as measured by hemagglutination inhibition) reacted with any of the 44 peptides with an OD of Ͼ0.2 (Fig. 1b) . The mean reactivities of human sera with p32 and p35 were determined by endpoint titration ELISA, which gave titers of 1/3,200 and 1/400, respectively.
Immunogenicity of p32 and p35 in BALB/c and CBA mice. IgG antibodies to peptides p32 and p35 were demonstrable in BALB/c and CBA mice following intraperitoneal priming with peptide in Freund's complete adjuvant and boosting with peptide in incomplete Freund's adjuvant 3 weeks later. With p32 as an immunogen, antipeptide antibodies were detectable before the boost, and titers continued to increase for 5 weeks after priming. The maximum anti-p32 antibody titers in BALB/c mice (log 10 4.1) were 1 log 10 higher than those in CBA mice. When p35 was used as an immunogen in BALB/c mice, antipeptide antibodies were detectable after priming and reached a maximum titer of log 10 4.75 after the boost. However, anti-p35 antibodies in CBA mice were detectable only following the boost (maximum titer, log 10 1.9). A control 15-mer peptide from the F protein, p17 (aa 238 to 252), which was not antigenic with human anti-MV antisera, failed to generate antipeptide antibodies when used as an immunogen in either BALB/c or CBA mice (data not shown).
Reactivities of anti-p32 and anti-p35 antibodies with MV. Antipeptide antisera raised in BALB/c and CBA mice were tested for cross-reactivity with MV in ELISA. Anti-p32 antibodies from both BALB/c and CBA mice were cross-reactive with MV at low dilutions (Fig. 2) , neutralized MV infectivity in a plaque inhibition assay (Table 1) , but did not inhibit MVinduced cell-cell fusion (fusion from within) (data not shown). Anti-p35 antibodies from both strains failed to cross-react with MV.
Affinities of mouse antipeptide antibodies for p32. The relative affinities of antipeptide antibodies to p32 raised in BALB/c and CBA mice were assessed by an inhibition enzyme immunoassay. The relative affinities of antipeptide antibodies for the homologous peptide raised in CBA mice were significantly higher than those of antipeptide antibodies raised in BALB/c mice (P ϭ 0.03 [ Table 1 
]).
Characterization of the fine specificity of binding of p32 sequence by human sera. The 18 postinfection samples were tested for reactivity with overlapping 8-mer peptides representing the original 15-mer p32 peptide used as solid-phase antigens on ELISA. Table 2 (assay A) show that 33.3% of the human serum samples reacted with peptide p32-2. The relative antibody affinities of polyclonal human antisera for the 15-mer peptide and the overlapping 8-mer peptides were assessed by a solid-phase inhibition ELISA (Table 2 , assay A). The polyclonal human antibodies had significantly higher relative affinities for the original 15-mer peptide p32 than the 8-mer peptides. To investigate further the role of cysteine residues and possible disulfide bond formation in antigenic recognition, two additional 15-mer peptides containing conserved amino acid substitutions (serine for cysteine at positions 390, 395, and 397 and serine for cysteine at positions 390 and 397) were synthesized and used as solid-phase antigens on ELISA. None of the acute postinfection sera recognized the substituted peptides ( Table 2, 
assay B).
Passive protection studies. Only p32 induced mouse antipeptide antibodies which cross-reacted with MV on ELISA and also inhibited MV infectivity in a plaque assay. Therefore, each mouse in two groups of 12-day-old BALB/c offspring was passively immunized with 150 l of anti-p32 antiserum raised in BALB/c mice (with an average antipeptide titer of log 10 4.1) (6 mice) or CBA mice (with an average antipeptide titer of log 10 3.1) (5 mice) or with normal mouse serum (10 mice), followed by intracranial inoculation of neuroadapted MV 1 day later. The passive transfer of either BALB/c or CBA immune serum conferred significant protection against fatal MV encephalitis (P ϭ 0.001 and P ϭ 0.022, respectively). No significant difference in protection was observed between mice receiving antipeptide serum from either BALB/c or CBA mice (P ϭ 0.545 [ Fig. 3]) . Sequence analysis of p32. The amino acid sequence of the 15-mer p32 (aa 388 to 402 [ Table 3 ]) is conserved in all morbilliviruses (6) , and the cysteine residues within the p32 sequence are conserved among other paramyxoviruses (3). Screening of the Swissprot database revealed no significant homology between p32 and any other human, animal, or plant viral proteins.
DISCUSSION
In spite of the availability of a live attenuated vaccine, more than 1 million childhood deaths from measles occur annually. This worrying statistic emphasizes the requirement for alternative vaccine strategies. The potential use of synthetic peptides as a vaccine against MV has previously been studied in experimental animals (16, 17, 19, 24) . In the work described here, polyclonal human anti-MV antisera were used to identify antigenic and immunogenic peptides which represent linear B-cell epitopes from the F protein of MV. Overlapping F peptides were screened with acute postmeasles sera, obtained from African children, to map linear B-cell epitopes. A single antigenic peptide, p32, representing aa 388 to 402 of the F protein, was recognized by all of the serum samples obtained from infected children but by none of the sera with undetectable anti-MV antibodies. Previous analysis of immunodominant recognition sites of the F protein with human sera by using overlapping peptides revealed 7 to 10 binding regions which were located along the whole F sequence (14, 28) . In the absence of anti-MV-negative antisera in these studies, the heterogeneity of antigenic regions observed may represent nonspecific binding of convalescent sera to some of the peptides. Although no immune function for these antibody binding regions was shown, peptide p32 was included in one such antigenic region as being recognized by more than 50% of convalescent sera (28) . Furthermore, these antibody binding regions were found to lie near experimentally defined helper T-cell epitopes, thus providing evidence for nonrandom spanning of T-and B-cell epitopes (13) . The apparent discrepancy between the data in reference 28 and those in the present study may arise from the fact that Wiesmuller et al. used late convalescent European sera, whereas our sera were from African children in the acute stage of MV infection.
Peptide p32 represents a sequence within the cysteine-rich region of the F 1 subunit of the protein, which is known to be highly conserved among paramyxoviruses (22) . Following further characterization of this sequence by using shorter versions of the original p32 peptide, approximately 35% of acute postmeasles polyclonal sera were shown to react with the shorter peptide containing a cysteine residue at each terminus. However, the sera bound with the highest affinity to the parent 15-mer peptide. Moreover, the polyclonal sera failed to recognize the substitution peptides with conserved replacements at b Assessed by a solid-phase inhibition ELISA, using peptides as fluid phase inhibitors.
* P Ͻ 0.001 significant difference of affinities between original 15-mer peptide and the 8-mer peptides. ND, not determined.
c Percentage positivity and mean relative affinity of 18 human polyclonal anti-MV antibodies for the peptide p32 as a 15-mer and as overlapping 8-mers.
d Recognition of 18 human anti-MV antisera with two further 15-mer peptides in which two or three of the cysteines were replaced by serines. FIG. 3 . Effect of passive immunization of BALB/c mice with anti-p32 serum raised in BALB/c (log 10 4.1) and in CBA mice (log 10 3.1) on the response to challenge with the neuroadapted strain of MV. Groups of 2-week-old BALB/c mice received 150 l of either anti-p32 serum derived from BALB/c or CBA mice or normal mouse serum (NMS). Survival in mice receiving BALB/c serum (83%) was significantly different from that in control mice. Survival in mice receiving CBA serum (60%) was also significantly different from that in control mice. the site of the cysteine residues, thus establishing the requirement of cysteines for the antigenic conformation of the peptide. The cysteine-rich region of the MV F glycoprotein (aa 337 to 423), comprising eight cysteine residues, interacts specifically with MV H protein to induce cell fusion, and a limited region, Cys 337 to Arg 381 , is all that is required for fusion (30) . Furthermore, in an MV F-protein mutant in which two amino acid changes occurred within the cysteine-rich region (aa 330 to 390), replication could no longer be inhibited by a fusioninhibiting peptide (12) . However, the lack of recognition of all peptides representing the regions within the cysteine-rich domain by polyclonal human serum samples in this study suggests that these peptides do not assume the correct conformation on a solid-phase support.
Peptide p32 was shown to be immunogenic in two strains of mice and induced antipeptide antibodies which cross-reacted with MV and inhibited MV infectivity in vitro. The anti-p32 antibodies were effective in a plaque inhibition assay but did not inhibit MV-induced cell-cell fusion. It therefore appears that these antibodies inhibit fusion from without (23, 29) by binding to the appropriate epitope on the F protein of the virus.
The ability of p32 peptide alone to induce an antibody response indicates the existence of both an antigenic B-cell epitope and a helper T-cell epitope within its sequence. Furthermore, a boosting effect observed 3 weeks following priming in the two strains of mice provides further evidence of T-cell help in the induction of memory B cells. The immunogenicity of this peptide in two inbred strains of mice (H-2 d and H-2 k ) suggests that the helper T-cell epitope is non-major histocompatibility complex restricted. However, determining whether the amino acid sequence of p32 comprises a promiscuous helper T-cell epitope, capable of presentation by a wide range of major histocompatibility complex class II molecules, would require immunogenic studies on further inbred strains of experimental animals. Linear sequences which comprise both B-and T-cell epitopes have been described previously (9) . Antiviral neutralizing monoclonal antibodies have generally been considered to be directed toward conformational epitopes, with the role played by linear B-cell epitopes being debatable. However, linear epitopes have been shown to induce neutralizing antibodies against foot-and-mouth disease virus (9) and human immunodeficiency virus (18) .
In the present study, antibodies raised to the linear peptide p32 afforded passive protection to mice against a fatal encephalitis following challenge with a neuroadapted MV. As the peptide contained three cysteine residues within its sequences, the possibility exists that disulfide bonds can be formed to allow the peptide to adopt a cyclic secondary structure which mimics an external loop on the native protein. Antibodies to this structure would thus be able to cross-react with the virus and neutralize its infectivity.
Passively transferred anti-p32 antibodies induced in both BALB/c and CBA mice were similarly protective, although the antipeptide antibody titers in BALB/c mice were higher, and the inhibition of MV infectivity in vitro was similar. However, the anti-p32 antibodies raised in CBA mice had a significantly higher relative antibody affinity for the homologous peptide. Earlier reports have indicated that little association exists between the level and affinity of antiprotein antibodies in different strains of inbred mice (25) . In addition, the affinity of antibodies for synthetic peptides has previously been shown to affect the passive and active protection afforded in vivo (16) . In the present study, mice receiving passively transferred BALB/c or CBA antipeptide sera were protected against a fatal encephalitis following challenge with neuroadapted MV, thus providing further evidence that the affinity of the antibodies raised is an important factor in their protective capacity.
The results presented here illustrate the potential of the use of acute postmeasles human sera for the identification of peptide sequences representing single immunodominant regions within MV F protein which may be used as immunogens for the induction of neutralizing and protective antibodies. Although the sample numbers tested are small, the results of the work presented here clearly identify an important antigenic and immunogenic determinant from the conserved region of MV F protein which has potential for use in an immunodiagnostic assay for MV antibodies. Moreover, these results indicate that this epitope represents a candidate for inclusion, along with other protective epitopes, in a subunit vaccine for MV. b Asterisks indicate conserved residues.
